Kessel Christoph, Rossig Claudia, Abken Hinrich
Translational Inflammation Research, Department of Pediatric Rheumatology & Immunology, University of Münster Faculty of Medicine, Munster, Germany.
Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Munster, Germany.
J Immunother Cancer. 2025 Jan 14;13(1):e010545. doi: 10.1136/jitc-2024-010545.
Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also a powerful driver of hyperinflammatory conditions, we discuss to what extent unleashing IL-18 is a double-edged sword in CAR T cell therapies.
嵌合抗原受体（CAR）T细胞疗法对实体癌的治疗效果仍未达预期；在首次临床试验中，通过添加白细胞介素-18（IL-18）来提供细胞因子辅助已显示出显著疗效。由于IL-18也是引发过度炎症状态的强大驱动因素，我们探讨了在CAR T细胞疗法中释放IL-18在多大程度上是一把双刃剑。
